Luminex Corp. has completed the acquisition of Merck KGaA's cell analysis equipment provider MilliporeSigma in a $75 million cash, stock and asset deal.
The acquisition expands the Austin, Texas-based company's footprint in life science research and broadens its existing offering of flow-based detection systems. The portfolio includes flow cytometry products sold under the brand names Amnis, for cell-based analysis, and Guava, which are high-performance systems based on microcapillary technologies.
Luminex expects the acquisition to contribute $40 million to $50 million toward its 2019 revenues.
Cantor Fitzgerald & Co. acted as financial adviser and Smith Gambrell & Russell LLP served as legal counsel to Luminex.